focus -WSS

focus

author：leisure time 2025-10-01 01:50:39 - browse：19

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Ascension's ugly legal battle over care for poor patients in Texas

WSS

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Physician assistants need a new name. Here's what it should be

Boston Scientific acquires urology company Axonics for $3.7 billion

Fed up with FDA, ALS advocates consider a take

Covid’s new normal has set in amid another rise in cases

House panel takes first step toward fixing drug shortages

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

Akili changes sales model for its ADHD video game treatment

BioMarin wins approval for gene therapy to treat hemophilia A

How the messy conversation about Dolly changed bioethics

Continuity nursing helped my family in our darkest PICU moments

Male doctors called my cancer incurable. A female doctor showed it wasn't

At least 13 dead in Texas as scorching temps continue

People with substance use disorder deserve online privacy

United colonoscopy coverage change 'may cost lives,' doctors say

'A game

leisure time

Study suggests new cause of Down syndrome: cells linked to aging

Profiling embryos to choose those with higher IQs is almost a reality

'A game

Merck to acquire Harpoon Therapeutics for $680 million

STAT Virtual Event: JPM Recap, Live!

Physician assistants need a new name. Here's what it should be

hotspot

focus

focus

leisure time